RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet

Summary

Previous research has confirmed that hemorrhage is among the most commonly encountered pregnancy complications in the Tibet Autonomous Region (TAR). This trial will test the effectiveness of a traditional Tibetan drug (Zhi Byed 11) vs. misoprostol to prevent postpartum hemorrhage (PPH) among women delivering vaginally in three hospitals in Lhasa, TAR.

Conditions

• Hemorrhage

Interventions

DRUG

Zhi Byed 11

Sponsors & Collaborators

• Global Network for Women's and Children's Health Research

  collaborator OTHER

• Bill and Melinda Gates Foundation

  collaborator OTHER

• Fogarty International Center of the National Institute of Health

  collaborator NIH

• National Center for Complementary and Integrative Health (NCCIH)

  collaborator NIH

• National Institute of Dental and Craniofacial Research (NIDCR)

  collaborator NIH

• National Cancer Institute (NCI)

  collaborator NIH

• RTI International

  collaborator OTHER

• University of Utah

  collaborator OTHER

• Health Bureau Tibet Autonomous Region

  collaborator UNKNOWN

• University of California, San Francisco

  collaborator OTHER

• One Heart Project

  collaborator UNKNOWN

• NICHD Global Network for Women's and Children's Health

  lead NETWORK

Principal Investigators

• Michael Varner, MD · University of Utah

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

FEMALE

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2005-09-30

Completion

2007-03-31

Countries

• China

Study Locations